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Abstract
Background: To study the expression of MK-1 and RegⅣ and to detect their pathological significances in benign
and malignant lesions of gallbladder.
Methods: The expression of MK-1 and RegⅣ was detected by immunohistochemical method in paraffin-
embedded sections of surgical resected specimens from gallbladder adenocarcinoma (n = 108), peritumoral tissues
(n = 46), adenomatous polyp (n = 15), and chronic cholecystitis (n = 35).
Results: The positive rate of MK-1 or RegⅣ expression was significantly higher in gallbladder adenocarcinoma
than that in peritumoral tissues (c
2
MK-1 = 18.76, P < 0.01; c
2
RegⅣ = 9.92, P < 0.01), denomatous polyp (c
2
MK-1 =
9.49, P < 0.01; c
2
RegⅣ = 8.59, P < 0.01) and chronic cholecystitis (c
2
MK-1 = 24.11, P < 0.01; c
2
RegⅣ = 19.24, P < 0.01).
The positive cases of MK-1 and/or RegⅣ in the benign lesions showed moderately- or severe-atypical hyperplasia
of gallbladder epitheli. The positive rates of MK-1 were significantly higher in the cases of well-differentiated
adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues than those in the ones of
differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional tissues in gallbladder
adenocarcinoma (P < 0.05 or P < 0.01). On the contrary, the positive rates of RegⅣ were significantly lower in the
cases of well-differentiated adenocarcinoma, no-metastasis of lymph node, and no-invasiveness of regional tissues
than those in the ones of differentiated adenocarcinoma, metastasis of lymph node, and invasiveness of regional
tissues in gallbladder adenocarcinoma (P < 0.05 or P < 0.01). Univariate Kaplan-Meier analysis showed that
decreased expression of MK-1 (P = 0.09) or increased expression of RegⅣ (P = 0.003) was associated with
decreased overall survival. Multivariate Cox regression analysis showed that decreased expression of MK-1 (P =
0.033) and increased expression of RegⅣ (P = 0.008) was an independent prognostic predictor in gallbladder
adenocarcinoma.
Conclusions: The expression of MK-1 and/or RegⅣ might be closely related to the carcinogenesis, clinical
biological behaviors, and prognosis of gallbladder adenocarcinoma.
Keywords: gallbladder neoplasms, gallbladder polyp, chronic cholecystitis, tumor-associated antigen, MK-1, regen-
erating gene ?Ⅳ?, immunohistochemistry
Introduction
MK-1, also known as Ep-CAM, is a type-I transmem-
brane protein with cell adhesion activity expressed on
normal epithelial cells of various tissues including sto-
mach, colon, pancreas, lung, breast and ovary. MK-1 has
been suggested to be involved in the differentiation and
growth of epithelial cells under normal physiological
conditions through its homotypic cell-cell adhesion
activity [1-5]. Because it is over-expressed on most car-
cinomas, MK-1 has been used as a target for diagnosis
and therapy of cancer [1-5]. The regenerating gene
(Reg) family, a group of small secretory proteins, is
involved in cell proliferation or differentiation in diges-
tive organs, is upregulated in several gastrointestinal
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any medium, provided the original work is properly cited.cancers, and functions as trophic or anti-apoptotic fac-
tors [6-11]. RegIV, a member of the regenerating gene
family, is involved in digestive tract malignancies,
including the stomach, colorectum, and pancreas, as
well as in benign diseases such as ulcerative colitis
[6-11]. RegIV overexpression in tumor cells has been
associated with cell growth, survival, adhesion, and resis-
tance to apoptosis [6-11]. Although the expression of
MK-1 has been reported in carcinomas of various ori-
gins, only one study has described its expression in gall-
bladder adenocarcinoma. No study on the expression of
RegIV in gallbladder adenocarcinoma has been pub-
lished. In the present study, we studied the expression
of MK-1 and RegⅣ in various benign and malignant
lesions of gallbladder, and evaluated their prognostic
usefulness.
Materials and methods
Patients and clinical information
A total of 204 specimens, including 108 adenocarcino-
mas, 46 peritumoral tissues, 35 chronic cholecystitis tis-
sues, and 15 gallbladder polyp, were studied ethically
with pre-approval from Ethics Committee of Human
Study of Central South University. All of these samples
were collected between 1996 and 2006. Among the 108
adenocarcinoma, 31 cases are male (28.7%) and 77 cases
are female (71.3%) with an average age of 52.6 ± 11.2
years. Diagnoses of adenocarcinomas were based on
morphological criteria, immunohistochemical staining,
and the clinical findings. The histopathologic subtypes
of the 108 adenocarcinomas include 36 well-differen-
tiated adenocarcinomas (33.3%), 31 moderately-differen-
tiated adenocarcinomas (28.7%), 30 poorly-differentiated
adenocarcinomas (27.8%), and 11 mucinous adenocarci-
nomas (10.2%). The invasion was evaluated according to
the standard criteria for T-stages [12]. Among the 108
adenocarcinomas, 14 cases are T1, 35 cases are T2, 37
cases are T3, and 22 causes are T4 stage. Invasion of
gallbladder surrounding tissues and organs was found in
59 patients (54.6%) with adenocarcinoma while 59
patients had regional lymph node metastasis (54.6%). 58
cases had gallstones (53.7%). Surgery included radical
resection for 34 adenocarcinoma (31.5%), palliative sur-
gery for 48 adenocarcinomas (44.4%) and no resection
operation for 26 cases (24.1%) (The specimens were
obtained with surgical biopsy in these patients). Survival
information of 67 cases among the 108 adenocarcino-
mas was obtained through letters and phone calls.
Among them, 20 cases survived over 1 year and 47
cases survived less than 1 year. The chronic cholecysti-
tis, gallbladder polyp and peritumoral tissues were diag-
nosed according to the published standard criteria [13].
The 46 peritumoral tissues (distance from cancer ≥ 3
mm) were obtained from the 108 patients with
adenocarcinomas. Among them, 10 tissues are normal,
10 tissues are mild dysplasia, 12 tissues are moderate
dysplasia, and 14 tissues are severe dysplasia. Among
the 35 cases with chronic cholecystitis, 15 cases are
males (42.9%) and 20 are females (57.1%). According to
the criteria for dysplasia described by Dowling and Kelly
[14], the 35 cases of chronic cholecystitis (15 have
chronic cholecystitis only and 20 have chronic cholecys-
titis accompanied by gallbladder stone) were classified
into normal and mild, moderate, and severe dysplasia:
11 cases without cellular atypia as normal mucosa, 12
cases with mild cellular atypia as mild dysplasia, 7 cases
with moderate cellular atypia as moderate dysplasia, and
5 cases with severe cellular atypia as severe dysplasia.
Among the 15 polyps, 10 were confirmed to have
epithelial normal to mild dysplasia by pathological
examination and 5 have moderate to severe dysplasia.
EnVision immunohistochemistry
Four-micrometer-thick sections were cut from routinely
paraffin-embedded tissues. Immunostaining was per-
formed using a peroxidase-based EnVision™ Detection
kit (Dako Laboratories, Carpinteria, CA, USA) following
the user manual. The mouse anti-MK-1, rabbit anti-
RegIV and HRP-conjugated second antibodies were pur-
chased from Santa Cruz Biotechnology, Inc. (Santa
Cruz, CA, USA).
Pathological evaluation
Stained slides were evaluated in a blinded manner in all
cases for membrane and cytoplasm staining. MK-1 and
RegIV expression was defined as the presence of specific
staining on the surface membranes and cytoplasm of
tumor cells. MK-1 and RegIV expression was considered
as positive when over 25% of tumor cells exhibited a
positive reaction [13,15].
Statistical analysis
Data was analyzed using the statistical package for the
Social Sciences Version 13.0 (SPSS 13.0). The inter-rela-
tionship of MK-1 or RegIV expression with histology or
clinical factors was analyzed using c
2 or Fisher’se x a c t
test. Kaplan-Meier and log-rank test were used for uni-
variate survival analysis. Cox proportional hazards
model was used for multivariate analysis and to deter-
mine the 95% confidence interval. Results were consid-
ered significant if a two-sided P value of less than 0.05
was obtained.
Results
MK-1 and RegIV expression in benign and malignant
lesions of gallbladder
The expression of MK-1 and RegIV was primarily
located in the membrane and cytoplasm (Figure 1). The
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adenocarcinoma samples was significantly higher than in
peritumoral tissues, polyp or chronic cholecystitis (P <
0.01) (Table 1). Among the 108 gallbladder adenocarci-
noma samples, 67 of them were MK-1 positive (62.0%)
and 58 were RegIV positive (53.7%). The positively
expressed peritumoral tissue, polyp and chronic chole-
cystitis showed atypical hyperplasia of epitheli.
MK1 and RegIV expression is associated with the
clinicopathological characters of adenocarcinoma
In adenocarcinomas that were highly differentiated, with
tumor diameter < 2 cm, with no lymph node metastasis
and no peritissue invasion, MK-1 positive expression
rate was significantly higher than those that were mod-
erately- or low-differentiated, with tumor maximum dia-
meter ≥ 2 cm, with lymph node metastasis and
peritissue invasion (P < 0.05). The expression of RegIV
showed opposite pattern (P < 0.05). The expression of
MK-1 and RegIV showed no obvious relation with other
clinicopathological characters, such as age, sex or chole-
cystolithiasis (P > 0.05) (Table 2).
Relationship between MK-1 and RegIV expression and the
lifetime of patients with gall bladder adenocarcinoma
According to survey by mail or phone (2 years), we got
67 profiles from the 108 gallbladder adenocarcinoma, 20
of them survived more than or equal to 1 year after sur-
gery, 47 of them had less than 1 year life cycle, and
mean life cycle was 9.6 ± 5.2 months. Among the 67
cases, the positive expression of MK-1 and RegIV was
38 (56.7%) and 34 (50.7%). After Kaplan-Meier survival
analysis, we found that the mean survival time after sur-
gery was closely related to pathological types (P =
0.031), maximum diameter of tumor (P = 0.003), lym-
phatic metastasis status and peritissue invasion (P=
0.002). The mean survival time after surgery was signifi-
cantly higher in the MK-1 positive cases than the nega-
tive ones (P = 0.009), while the mean survival time after
surgery was significantly lower in the RegIV positive
cases than the negative ones (P = 0.003) (Figure 2).
Table 3 summarizes the results of multivariate survival
analysis using the Cox proportional hazards model.
Multivariate analysis revealed that maximum diameter
of tumor ≥ 2 cm, lymphatic metastasis and peritissue
invasion, MK-1 negative expression and RegIV positive
expression were negatively correlated with mean survival
time after surgery, positively correlated with mortality,
and are independent prognostic markers.
Discussion
Our study shows the prognostic significance of MK-1
and RegIV expression as a tumor biological marker in
patients with gallbladder adenocarcinoma. We found
that positive expression rate of MK-1 and RegIV were
higher in gallbladder adenocarcinoma than those in
peritumoral tissues, polyp and chronic cholecystitis. Sta-
tisitical analysis revealed that MK-1 negative expression
and RegIV positive expression is negatively correlated
with mean survival time after surgery, positively corre-
lated with mortality, and are independent prognostic
markers.
Figure 1 Expression of MK1 and RegIV in the benign and
malignant lesions of gallbladder. EnVision immunohistochemistry,
original magnification x200. MK1 and RegIV positive reaction was
mainly localized in the cell membrance and/or cytoplasm. A, MK1
positive expression in peri-tumor tissue with moderate atypical
hyperplasia. B, MK1 positive expression in highly differentiated gall
bladder adenocarcinoma. C, RegIV positive expression in polyp with
severe atypical hyperplasia. D, RegIV positive expression in
moderately differentiated gall bladder adenocarcinoma.
Table 1 Relationship between ANXA1 and ANXA2 expression and the lifetime of gall bladder adenocarcinoma
Type Case Number MK-1 RegIV
Positive Cases (%) c
2 P Positive cases (%) c
2 P
Gall bladder adenocarcinoma 108 67 (62.0) 58 (53.7)
Peri-tumor tissues 46 11 (23.9) 18.76 < 0.01 12 (26.1) 9.92 < 0.01
Gall bladder polyp 15 3 (20.0) 9.49 < 0.01 2 (13.3) 8.59 < 0.01
Chronic cholecystitis 35 5 (14.3) 24.11 < 0.01 4(11.4) 19.24 < 0.01
Compared with Gall bladder adenocarcinoma
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Clinical Pathological Characters Number
of cases
MK-1 RegIV
Positive cases (%) c
2 P Positive cases (%) c
2 P
Sex
Male 24 16 (66.7) 0.28 > 0.05 11 (45.8) 0.77 > 0.05
Female 84 51 (60.7) 47 (56.0)
Age
≤ 45 yr 31 19 (61.3) 0.01 > 0.05 15 (48.4) 0.49 > 0.05
> 45 yr 77 48 (62.3) 43 (55.8)
Pathological type
Highly differentiated 36 29 (80.6) 16.35 < 0.01 12 (33.3) 9.94 < 0.05
Moderately differentiated 31 20 (64.5) 19 (61.3)
Low differentiated 30 10 (33.3) 21 (70.0)
Mucous adenocarcinoma 11 8 (72.7) 6 (54.5)
Maximal diameter
< 2 cm 31 23 (74.2) 2.73 > 0.05 13 (41.9) 2.42 > 0.05
≥2 cm 77 44 (57.1) 45 (58.4)
Lymphatic metastasis
None 49 39 (79.6) 11.74 < 0.05 20 (40.8) 4.24 < 0.05
Yes 59 28 (47.6) 38 (64.4)
Peritissue invasion
None 49 37 (75.5) 6.91 < 0.05 21 (42.9) 4.24 < 0.05
Yes 59 30 (50.9) 37 (62.7)
Cholecystolithiasis
None 50 28 (56.0) 1.44 > 0.05 24 (48.0) 1.22 > 0.05
Yes 58 39 (67.2) 34 (58.6)
Figure 2 MK1 and RegIV expression and survival in patients with adenocarcinoma of gallbladder. A, Kaplan-Meier plots of overall survival
in patients with gallbladder adenocarcinoma and with MK1 positive and negative expression. B, Kaplan-Meier plots of overall survival in patients
with gallbladder adenocarcinoma and with RegIV positive and negative expression.
Yang et al. Diagnostic Pathology 2011, 6:100
http://www.diagnosticpathology.org/content/6/1/100
Page 4 of 6The expression of MK-1 has been previously reported
in several carcinomas. In gastric carcinomas, MK-1 is
more frequently expressed in cardiac tumors (with 50%
expression rate), in large (> 3 cm) tumors, and in speci-
mens from patients with more than five metastatic
lymph nodes [2]. In urinary bladder carcinoma, 56.8%
were positive for MK-1 protein expression and signifi-
cant correlations were observed between MK-1 expres-
sion and tumor grade, schistosoma, DNA ploidy and
tumor recurrence [3]. In Gallbladder carcinoma, expres-
sion of MK-1 was found in 50 (79%) of 63 tumor sam-
ples. Multivariate analysis showed that MK-1 expression
was an independent prognostic marker, and Kaplan-
Meier curves showed that MK-1 expression was signifi-
cantly related to increased overall survival, suggesting
that MK-1 expression is a prognostic marker in gallblad-
der carcinoma [4]. In our study the positive expression
rate of MK-1 was slightly lower than what was pre-
viously reported (62% vs 79%), however, our statistical
analysis revealed similar prognostic significance of MK-1
expression.
The expression of RegIV has also been reported to be
increased in some carcinomas including prostate, pan-
creatic and gastric cancer [6-11]. The expression of
RegIV has been found to be related to the carcinogen-
esis, clinical biological behaviors, and prognosis of the
carcinomas studied. Most of the high RegIV cases have
poorly differentiated, high clinical stage, prone to metas-
tasis and strong invasion ability, which are all consid-
ered being bad indicators of cancer prognosis [6-11,16].
These results all support that RegIV may involve in can-
cer formation and affect its development and prognosis.
To the best of our knowledge our study is the first of
RegIV expression in gallbladder adenocarcinoma. We
showed that the positive expression of RegIV in gall-
bladder adenocarcinoma samples was significantly
higher than in benign gallbladder lesions. In adenocarci-
nomas, MK-1 positive expression rate was significantly
higher in samples that were highly differentiated, with
tumor diameter < 2 cm, with no lymph node metastasis
and no peritissue invasion. Moreover, RegIV positive
expression was negatively correlated with mean survival
time after surgery, positively correlated with mortality,
and are independent prognostic markers. These findings
indicate that RegIV is a promising tumor marker in gall-
bladder adenocarcinoma.
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